Akebia Therapeutics, Inc. (AKBA) 追踪市盈率为负值 -70.7, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 21.4 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -1.41%, 前瞻盈利收益率 4.68%. PEG 0.11 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 45/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -2.9 | -0.05 | 5.76 | 255.79 | - |
| 2017 | -8.4 | 0.17 | 5.42 | 3.63 | - |
| 2018 | -3.8 | 0.22 | 1.02 | 3.11 | - |
| 2019 | -2.7 | -0.04 | 1.90 | 2.23 | - |
| 2020 | -1.0 | -0.14 | 1.57 | 1.32 | - |
| 2021 | -1.3 | 0.03 | 5.07 | 1.77 | - |
| 2022 | -1.1 | 0.02 | 20.17 | 0.36 | - |
| 2023 | -4.5 | 0.09 | -7.60 | 1.19 | - |
| 2024 | -5.8 | -0.32 | -8.15 | 2.50 | - |
| 2025 | -77.5 | 0.83 | 12.70 | 1.75 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-3.60 | $1.54M | $-135.75M | -8843.5% |
| 2017 | $-1.77 | $177.98M | $-76.91M | -43.2% |
| 2018 | $-1.47 | $207.74M | $-171.9M | -82.7% |
| 2019 | $-2.36 | $335M | $-279.66M | -83.5% |
| 2020 | $-2.53 | $295.31M | $-349.87M | -118.5% |
| 2021 | $-1.48 | $213.58M | $-244.87M | -114.7% |
| 2022 | $-0.58 | $292.6M | $-106.01M | -36.2% |
| 2023 | $-0.28 | $194.62M | $-51.93M | -26.7% |
| 2024 | $-0.33 | $160.18M | $-69.41M | -43.3% |
| 2025 | $-0.02 | $236.2M | $-5.35M | -2.3% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.06 | $-0.15 – $0.01 | $231.42M | $215.91M – $252.34M | 3 |
| 2027 | $-0.14 | $-0.22 – $-0.07 | $192.88M | $191.87M – $194.62M | 3 |
| 2028 | $0.07 | $-0.01 – $0.25 | $252.26M | $201.83M – $296.69M | 4 |
| 2029 | $0.26 | $0.19 – $0.32 | $312.71M | $250.2M – $367.79M | 2 |
| 2030 | $0.64 | $0.47 – $0.78 | $424.05M | $339.28M – $498.74M | 2 |
